CN115708859B - 一种治疗过敏性鼻炎的药物组合物及其制备方法 - Google Patents
一种治疗过敏性鼻炎的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN115708859B CN115708859B CN202110966782.4A CN202110966782A CN115708859B CN 115708859 B CN115708859 B CN 115708859B CN 202110966782 A CN202110966782 A CN 202110966782A CN 115708859 B CN115708859 B CN 115708859B
- Authority
- CN
- China
- Prior art keywords
- parts
- under reduced
- reduced pressure
- prescription
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 46
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 208000024891 symptom Diseases 0.000 claims abstract description 35
- 241000132012 Atractylodes Species 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims description 207
- 239000000203 mixture Substances 0.000 claims description 113
- 230000002829 reductive effect Effects 0.000 claims description 82
- 239000000243 solution Substances 0.000 claims description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000000843 powder Substances 0.000 claims description 48
- 239000000341 volatile oil Substances 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 34
- 239000003826 tablet Substances 0.000 claims description 29
- 235000006533 astragalus Nutrition 0.000 claims description 28
- 241000931705 Cicada Species 0.000 claims description 27
- 241000218378 Magnolia Species 0.000 claims description 26
- 238000005303 weighing Methods 0.000 claims description 26
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 25
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 25
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 24
- 235000011477 liquorice Nutrition 0.000 claims description 24
- 241000213006 Angelica dahurica Species 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 17
- 241000045403 Astragalus propinquus Species 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 15
- 244000062241 Kaempferia galanga Species 0.000 claims description 14
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 14
- 241001061264 Astragalus Species 0.000 claims description 13
- 210000004233 talus Anatomy 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 238000001256 steam distillation Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 241001180876 Saposhnikovia Species 0.000 claims description 10
- 230000000172 allergic effect Effects 0.000 claims description 10
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 9
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 9
- 208000010668 atopic eczema Diseases 0.000 claims description 9
- 241000486679 Antitype Species 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 3
- 210000004072 lung Anatomy 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 39
- 210000000952 spleen Anatomy 0.000 abstract description 39
- 230000007812 deficiency Effects 0.000 abstract description 16
- 206010039101 Rhinorrhoea Diseases 0.000 abstract description 14
- 208000010753 nasal discharge Diseases 0.000 abstract description 12
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 9
- 230000009545 invasion Effects 0.000 abstract description 9
- 230000002085 persistent effect Effects 0.000 abstract description 9
- 206010052437 Nasal discomfort Diseases 0.000 abstract description 6
- 206010063659 Aversion Diseases 0.000 abstract 1
- 206010024642 Listless Diseases 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 208000017971 listlessness Diseases 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 119
- 229940079593 drug Drugs 0.000 description 106
- 241000700159 Rattus Species 0.000 description 52
- 238000012360 testing method Methods 0.000 description 43
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 30
- 201000010099 disease Diseases 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 28
- 230000037396 body weight Effects 0.000 description 26
- 210000001331 nose Anatomy 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 239000011734 sodium Substances 0.000 description 22
- 210000002850 nasal mucosa Anatomy 0.000 description 20
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 17
- 206010018691 Granuloma Diseases 0.000 description 16
- 229960001340 histamine Drugs 0.000 description 16
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 15
- 206010020751 Hypersensitivity Diseases 0.000 description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000035622 drinking Effects 0.000 description 14
- 230000002496 gastric effect Effects 0.000 description 14
- 238000007726 management method Methods 0.000 description 14
- 102000004388 Interleukin-4 Human genes 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000001717 pathogenic effect Effects 0.000 description 13
- 238000010171 animal model Methods 0.000 description 12
- 210000004400 mucous membrane Anatomy 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 11
- 230000003542 behavioural effect Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 229940092253 ovalbumin Drugs 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 10
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 9
- 238000012449 Kunming mouse Methods 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 229960003699 evans blue Drugs 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000005728 strengthening Methods 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108010021119 Trichosanthin Proteins 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 208000030961 allergic reaction Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 241000700198 Cavia Species 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 7
- 206010014025 Ear swelling Diseases 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 241001506371 Kadsura Species 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000013401 experimental design Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 230000008313 sensitization Effects 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 229960003291 chlorphenamine Drugs 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 238000005286 illumination Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 229940126673 western medicines Drugs 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 210000005081 epithelial layer Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 229940088336 primor Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000270 basal cell Anatomy 0.000 description 4
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 230000003862 health status Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 210000000492 nasalseptum Anatomy 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000008517 radix Trichosanthis Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000004876 tela submucosa Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- -1 OVA specific IgE Chemical compound 0.000 description 3
- 244000197580 Poria cocos Species 0.000 description 3
- 235000008599 Poria cocos Nutrition 0.000 description 3
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 241000046198 Triteleia hyacinthina Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 239000002662 enteric coated tablet Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001944 turbinate Anatomy 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 244000141218 Alpinia officinarum Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002334 Spandex Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000001774 alpinia officinarum Substances 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 210000000215 ciliated epithelial cell Anatomy 0.000 description 2
- 210000002777 columnar cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000009384 kangtai Substances 0.000 description 2
- 229960003630 ketotifen fumarate Drugs 0.000 description 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000004759 spandex Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000009571 yupingfeng Substances 0.000 description 2
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001002545 Engelhardia roxburghiana Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000004897 cough variant asthma Diseases 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ZPLUZNXSYCCJOE-UHFFFAOYSA-N phosphoric acid;propan-2-one Chemical compound CC(C)=O.OP(O)(O)=O ZPLUZNXSYCCJOE-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000024036 serous otitis media Diseases 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110966782.4A CN115708859B (zh) | 2021-08-23 | 2021-08-23 | 一种治疗过敏性鼻炎的药物组合物及其制备方法 |
PCT/CN2022/096580 WO2023024632A1 (zh) | 2021-08-23 | 2022-06-01 | 一种治疗过敏性鼻炎的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110966782.4A CN115708859B (zh) | 2021-08-23 | 2021-08-23 | 一种治疗过敏性鼻炎的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115708859A CN115708859A (zh) | 2023-02-24 |
CN115708859B true CN115708859B (zh) | 2024-03-08 |
Family
ID=85230241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110966782.4A Active CN115708859B (zh) | 2021-08-23 | 2021-08-23 | 一种治疗过敏性鼻炎的药物组合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115708859B (zh) |
WO (1) | WO2023024632A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526577A (zh) * | 2012-01-12 | 2012-07-04 | 颜颖 | 一种治疗过敏性鼻炎的药物 |
CN102579932A (zh) * | 2012-02-21 | 2012-07-18 | 常熟市方塔涂料化工有限公司 | 一种治疗过敏性鼻炎的药物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100337655C (zh) * | 2005-09-28 | 2007-09-19 | 骆斌 | 一种预防和/或治疗鼻鼽、变应性鼻炎的药物制剂 |
CN101637562A (zh) * | 2009-09-14 | 2010-02-03 | 黄山 | 一种过敏性鼻炎颗粒 |
-
2021
- 2021-08-23 CN CN202110966782.4A patent/CN115708859B/zh active Active
-
2022
- 2022-06-01 WO PCT/CN2022/096580 patent/WO2023024632A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526577A (zh) * | 2012-01-12 | 2012-07-04 | 颜颖 | 一种治疗过敏性鼻炎的药物 |
CN102579932A (zh) * | 2012-02-21 | 2012-07-18 | 常熟市方塔涂料化工有限公司 | 一种治疗过敏性鼻炎的药物 |
Non-Patent Citations (2)
Title |
---|
健鼻通窍汤治疗变应性鼻炎肺脾气虚证临床体会;李蕾等;《中国中医急症》;第18卷(第11期);第1898-1899页 * |
李淑良治疗变应性鼻炎经验;李蕾等;《江西中医药》;第49卷(第08期);第23-24页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115708859A (zh) | 2023-02-24 |
WO2023024632A1 (zh) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2520745C2 (ru) | Лекарственная композиция для лечения бронхита и способ ее получения | |
CN104208418A (zh) | 一种固精缩尿补肾的金樱子保健口服液及其制备方法 | |
CN105250821A (zh) | 一种用于治疗溃疡性结肠炎的中药复方制剂及其制备方法 | |
CN103341092B (zh) | 一种治疗萎缩性阴道炎的散剂制备方法 | |
CN114748603B (zh) | 一种防治新冠病毒肺炎变异或复阳的药物组合物和应用 | |
CN115708859B (zh) | 一种治疗过敏性鼻炎的药物组合物及其制备方法 | |
CN110368445A (zh) | 一种治疗银屑病的中药组合物及其制备方法和应用 | |
CN103301353B (zh) | 一种治疗萎缩性阴道炎的药物组合物 | |
CN104784549A (zh) | 用于治疗变应性鼻炎的内服中药 | |
CN104771578A (zh) | 用于治疗变应性鼻炎的中药 | |
CN114712478B (zh) | 一种治疗肠道疾病的中药组合物、制剂及其制备方法 | |
CN114712446B (zh) | 一种治疗胃病的中药组合物、制剂及其制备方法 | |
CN105250968A (zh) | 一种治疗哮喘的中药制剂 | |
CN111437309A (zh) | 治疗鼻炎的壮药组合物及其制备方法 | |
CN104352797A (zh) | 一种治疗晚期肺癌的中药及其应用 | |
CN115554372B (zh) | 一种治疗原发性纤维肌痛综合征的中药及制备方法和应用 | |
CN104758733A (zh) | 一种治疗老年性阴道炎的外洗剂 | |
CN114470110B (zh) | 一种有止痛作用的抗鼻炎中药组合物 | |
CN103316270B (zh) | 一种治疗产后会阴粘膜病变药物的散剂制备方法 | |
CN110433270B (zh) | 脱冰中药 | |
CN105687278A (zh) | 治疗中晚期肺癌的药物组合物 | |
CN105727237A (zh) | 一种含艾叶的治疗闭经的药物组合物 | |
CN105232816A (zh) | 一种用于治疗声带麻痹的中药 | |
CN112205494A (zh) | 一种生地清热茶及其制备方法 | |
CN104815233A (zh) | 一种治疗结核病的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231205 Address after: 050035 No. 238 Tianshan Avenue, Shijiazhuang hi tech Development Zone, Hebei, China Applicant after: Shijiazhuang Yiling Pharmaceutical Co.,Ltd. Address before: 102600 17 Tianfu street, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing Applicant before: BEIJING YILING PHARMACEUTICAL Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240509 Address after: 102600 17 Tianfu street, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: BEIJING YILING PHARMACEUTICAL Co.,Ltd. Country or region after: China Address before: 050035 No. 238 Tianshan Avenue, Shijiazhuang hi tech Development Zone, Hebei, China Patentee before: Shijiazhuang Yiling Pharmaceutical Co.,Ltd. Country or region before: China |